{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/ideaya-biosciences-announces-ide892-a-potential-best-in-class-mta-cooperative-prmt5-inhibitor-initiates-a-phase-12-clinical-combination-study-in-mtap-deleted-pancreatic-and-lung-cancers-302799642.html", "message": "News view counter 798612 successfully enlarged"}